A Comparison of PF708 and Forteo in Osteoporosis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Osteoporosis
Interventions
DRUG

Teriparatide (PF708)

Subcutaneous injection

DRUG

Teriparatide (Forteo)

Subcutaneous injection

Trial Locations (26)

16635

Altoona Center for Clinical Research, Duncansville

19610

Pennsylvania Regional Center for Arthritis & Osteoporosis Research, Wyomissing

24541

Spectrum Medical, Danville

30319

Atlanta Research Center, Atlanta

34748

OB-GYN Associates of Mid-Florida, Leesburg

35211

Radiant Research, Birmingham

36608

The Orthopaedic Group, Mobile

44311

Radiant Research, Akron

45236

Radiant Research, Cincinnati

58103

Lillestol Research, Fargo

60602

Radiant Research, Chicago

63044

Radiant Research, Bridgeton

68046

Radiant Research, Papillion

75093

Radiant Research, Plano

75231

Radiant Research, Dallas

78229

Radiant Research, San Antonio

78240

Radiant Research, San Antonio

80909

Radiant Research, Colorado Springs

85020

Radiant Research, Phoenix

85213

Radiant Research, Mesa

85224

Radiant Research, Chandler

85381

SunValley Arthritis Center, Peoria

87106

New Mexico Clinical Research & Osteoporosis Center, Albuquerque

89074

Radiant Research, Henderson

89128

Radiant Research, Las Vegas

98372

Radiant Research, Puyallup

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfenex, Inc

INDUSTRY